Coming October: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Columbia University at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Columbia University brings 4 presentations to SITC 2026 in Phoenix. Its program centres on CD4 T cells programmed into a Th1.17 killer state, which resist exhaustion and help grow stronger tumor-derived T cell products. One concrete item is a trial of an oral drug that breaks down the HPK1 protein, given alone or with a PD-1 antibody.

Organization

SITC 2026 Attendance

Columbia University

New York, NY

columbia.edu

Universities & research institutes

Private research university in New York City with a medical center and cancer center.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Th1.17-programmed cytotoxic CD4+ T cells (Th1.17-CTLs) are highly potent anti-tumor immune effectors with enhanced resistance to exhaustion and immunosuppression

Exhibition Halls 4-6 · Poster 295

Cell therapy · Tumor biology

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Trial in Progress: A Phase 1/2 Open-label Study of ARV-6723, an Oral PROTAC HPK1 Degrader, as Monotherapy or in Combination With an Anti-PD-1 Antibody in Patients With Advanced Solid Tumors

Exhibition Halls 4-6 · Poster 551

New agents · Clinical

Poster

Sat Nov 7
12:30–1:30pm
6:40–8:10pm

SBRT Combined with Adenosine Pathway Blockade and Anti-PD-1 Immunotherapy Induces Durable PSA Responses and Systemic T Cell Activation in Prostate Cancer: Immunological Insights from Two Patients

Exhibition Halls 4-6 · Poster 474

Clinical

Poster

Sat Nov 7
12:30–1:30pm
6:40–8:10pm

Th1.17-Programmed Platform for Generating Potent TILs Across Glioblastoma and Other Solid Tumors

Exhibition Halls 4-6 · Poster 354

Cell therapy

Session

Sat Nov 7
5:20pm–6:40pm

Cellular Therapies

Halls BC

Cell therapy

5:25pm–5:40pmGenetic, Structural, Chemical and In Situ Engineering of Cell TherapyYale School of Medicine
5:40pm–5:55pmLearnings From a CAR-T Driver Into Solid TumorMassachusetts General Hospital
5:55pm–6:10pmEx Vivo and In Vivo Genome Editing to Reprogram T Cell FunctionUCSF
6:10pm–6:25pmEnzyme-secreting CAR-T cells remodel the cancer glycocalyx to overcome mucin-mediated resistance in solid tumorsMassachusetts General Hospital

Instantly find 20 buyers from Columbia University

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction